Feeds:
Posts
Comments

Posts Tagged ‘Degarelix’

URO TODAY: Degarelix, a recently approved LHRH antagonist, has been shown to work more quickly in lowering serum testosterone levels, with acceptable safety and a mechanism that avoids the testosterone surges associated with LHRH agonist use. READ MORE>

Read Full Post »

URO TODAY: Swedish research shows a new treatment for advanced prostate cancer, the gonadotrophin-releasing hormone antagonist/receptor blocker Degarelix, is well tolerated, with no systemic allergic reactions. READ MORE>

This new agent represents an important pharmacological development in the hormonal treatment of prostate cancer.

Read Full Post »

AUGUST 6: MEDICAL NEWS TODAY:  The US Food and Drug Administration (FDA) has approved the trade name FIRMAGON (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. READ MORE>

Read Full Post »

JULY 16: URO TODAY: For testosterone suppression and PSA decline, new treatment degarelix compares well with standard hormonal therapy, for example, a  gonadotropin-releasing hormone agonist such as leuprolide. In fact, degarelix was associated with a faster testosterone suppression and PSA decline than leuprolide. READ MORE>

Read Full Post »

JUNE 19: NEW PROSTATE CANCER INFOLINK: It may be too early to make decisions about the real clinical utility of degarelix. READ MORE>

Read Full Post »

ADVANCEWEB.COM: Degarelix, a new drug for treatment of prostate cancer, has gained FDA approval.  A gonadotropin releasing hormone (GnRH) receptor inhibitor, the drug is intended to treat patients with advanced cancer, and slows the growth and progression of the cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer, according to FDA officials. READ MORE>

Read Full Post »